Effects of Far-infrared Ray on Temozolomide-treated Glioma in Rats

In Vivo. 2019 Jul-Aug;33(4):1203-1208. doi: 10.21873/invivo.11591.

Abstract

Background/aim: Malignant glioma is a rapidly progressive primary brain cancer. The aim of the study was to investigate the effect of far-infrared ray (FIR) on temozolomide (TMZ)-treated glioma in rats.

Materials and methods: Male, 8-week old, Fischer 344 inbred rats with glioma were randomly divided into three study groups (20 rats in each group). The control group received saline only once daily for 5 days. The TMZ group received TMZ (30 mg/kg) once daily for 5 days. The TMZ plus FIR group received TMZ (30 mg/kg) once daily for 5 days and infrared-c irradiation of 40 min twice daily for 4 weeks. The relative tumor fold and the expression of hypoxia-induced factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) were compared using one-way ANOVA at the end of study.

Results: The relative tumor fold of the TMZ+FIR group was significantly higher compared to the control group, and was borderline higher compared to the TMZ group at Day 7. The relative tumor fold of TMZ+FIR group was significantly higher compared to the control group and the TMZ group at Days 14, 21 and 28. HIF-1α expression of TMZ+FIR group was borderline higher compared to the control group at Day 28. The VEGF expression of TMZ+FIR group was significantly higher compared to the control group and the TMZ group at Day 28.

Conclusion: FIR might increase the growth of glioma under TMZ treatment in rats possibly via increasing VEGF expression, but not HIF-1α expression.

Keywords: Far-infrared ray; glioma; hypoxia-induced factor-1α; temozolomide; vascular endothelial growth factor.

MeSH terms

  • Animals
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Biomarkers
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • Combined Modality Therapy
  • Disease Models, Animal
  • Glioma / metabolism
  • Glioma / pathology
  • Glioma / therapy*
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Infrared Rays*
  • Male
  • Rats
  • Temozolomide / pharmacology*
  • Treatment Outcome
  • Tumor Burden / drug effects
  • Tumor Burden / radiation effects
  • Vascular Endothelial Growth Factor A / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents, Alkylating
  • Biomarkers
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Vascular Endothelial Growth Factor A
  • Temozolomide